CT-derived skeletal muscle change before immunotherapy predicts survival of advanced gastric cancer: associations with inflammatory markers and liver lipid metabolism

Background Skeletal muscle (SM) is a key factor in cancer treatment. However, it is unclear whether pretreatment SM change affects the outcome of immune checkpoint inhibitors (ICIs) therapy in gastric cancer (GC). Methods Advanced GCs treated with ICIs were retrospectively investigated. SM evaluated...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2024-09, Vol.29 (9), p.1255-1262
Main Authors: Hayano, Koichi, Ohira, Gaku, Matsumoto, Yasunori, Kurata, Yoshihiro, Otsuka, Ryota, Hirata, Atsushi, Toyozumi, Takeshi, Murakami, Kentaro, Uesato, Masaya, Matsubara, Hisahiro
Format: Article
Language:English
Subjects:
Body weight
C-reactive protein
Cancer Research
Cancer therapies
Gastric cancer
Immune checkpoint inhibitors
Immunotherapy
Leukocytes (neutrophilic)
Lipid metabolism
Liver cancer
Lymphocytes
Medicine
Medicine & Public Health
Metabolism
Monocytes
Musculoskeletal system
Oncology
Original
Original Article
Psoas muscle
Skeletal muscle
Surgical Oncology
Vertebrae
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Skeletal muscle (SM) is a key factor in cancer treatment. However, it is unclear whether pretreatment SM change affects the outcome of immune checkpoint inhibitors (ICIs) therapy in gastric cancer (GC). Methods Advanced GCs treated with ICIs were retrospectively investigated. SM evaluated by psoas muscle area at the third lumbar vertebra was measured on CT acquired within 1 month from the start of ICIs therapy (CT-1), and on CT acquired 2.8 ± 0.84 months before CT-1. Monthly change rate of SM (MCR-SM) was defined as the change rate of SMs between those two CTs divided by the period between those CTs (month). Monthly change rate of body weight (MCR-BW) during the same period was also calculated. They were compared with disease-specific survival (DSS) and progression-free survival (PFS). MCR-SM was compared with pretreatment markers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), C-reactive protein (CRP), and liver-to-spleen CT attenuation ratio (LSR) as a marker of liver lipid metabolism. Results This study enrolled eighty-three GC patients. MCR-SM significantly correlated with DSS and PFS ( P  
ISSN:1341-9625
1437-7772
1437-7772
DOI:10.1007/s10147-024-02551-x